Résultats d’un essai prospectif randomisé comparant une radiothérapie abdominopelvienne postopératoire et une chimiothérapie postopératoire dans les cancers de l’ovaire précoces

Kojs, Zbigniew; Gliński, Bogdan; Reinfuss, Marian; Pudełek, Jacek; Urbański, Krzysztof; Kowalska, Teresa; Kulpa, J

doi:10.1016/s1278-3218(00)00022-6

Cited by 20 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Followed up for 3 years Hreshchyshyn 1980 This trial compared chemotherapy against radiotherapy and no further treatment. The method of randomisation was not specified and a prognostic balance was not achieved in the different arms of the trial Klaassen 1988 This trial compared 3 different adjuvant treatments all given after pelvic radiotherapy: melphalan, whole abdominal radiotherapy and intraperitoneal radio-isotope therapy Kojs 2001 This trial compared adjuvant whole abdominal radiotherapy with CAP (cyclophosphamide, adriamycin and cisplatin) Maggioni 2006 This was a trial comparing systematic lymphadenectomy with lymph node sampling in apparent early stage ovarian cancer; it was not a trial of adjuvant treatment Mannel 2011 A randomised trial of maintenance low-dose paclitaxel for 24 weeks versus observation, in completely resected early-stage ovarian cancer patients receiving 3 cycles of chemotherapy (CP). Trial also known as GOG 175 Sell 1990 In this trial whole abdominal radiotherapy was compared to a combination of pelvic radiotherapy and cyclophosphamide.…”

Section: Characteristics Of Included Studies [Ordered By Study Id]mentioning

confidence: 99%

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Winter-Roach

Kitchener

Lawrie

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Adjuvant platinum-based chemotherapy is effective in prolonging the survival of the majority of patients who are assessed as having early (FIGO stage I/IIa) epithelial ovarian cancer. However, it may be withheld from women in whom there is well-differentiated encapsulated unilateral disease (stage 1a grade 1) or those with comprehensively staged Ib, well or moderately differentiated (grade 1/2) disease. Others with unstaged early disease or those with poorly differentiated tumours should be offered chemotherapy. A pragmatic approach may be necessary in clinical settings where optimal staging is not normally performed/achieved. In such settings, adjuvant chemotherapy may be withheld from those with encapsulated stage Ia grade 1 serous and endometrioid carcinoma and offered to all others with early stage disease.

show abstract

Section: Characteristics Of Included Studies [Ordered By Study Id]mentioning

confidence: 99%

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Winter-Roach

Kitchener

Lawrie

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Bowel obstruction was frequent in patients treated with 32 P (9%) and WAI (21%) when compared with to cisplatin arm (2%) (32). Because no survival benefit was shown with RT, cisplatin was recommended as the standard treatment for this subset of patients (Table 2) (33)(34)(35).…”

Section: Adjuvant Waimentioning

confidence: 99%

Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications

Flores-Balcázar¹,

Urías-Arce²

2020

Chin Clin Oncol

View full text Add to dashboard Cite

Epithelial ovarian cancer (OC) is known to be a neoplasm responsive to radiotherapy (RT).Nevertheless, the role of RT in the management of this disease represent a topic of controversy, and the indications for its use are not fully established. Initial studies suggested that the addition of RT in the form of intraperitoneal (IP) radioisotopes was useful. Indications for this treatment were peritoneal cytology with tumor cells, peritoneal implants, and capsule rupture. The instillation of radioisotopes was contraindicated when macroscopic residual disease was present. Pelvic RT was used after surgery in patients with an absence of gross residual disease. Early studies established the inadequacy of this technique and the need for treating the whole abdomen. Whole abdominal irradiation (WAI) was a therapeutic tool used in the prechemotherapy era to eradicate large amounts of microscopic peritoneal disease. Ideal candidates for WAI were stage I patients with grade 2 or 3 tumors; stage II patients with grade 1 or 2 tumors and residual disease, and stage III, grade 1 patients with <2 cm residual disease. The disadvantages of WAI were the dose-limiting toxicities, which were predominantly acute hematologic and late gastrointestinal. The era of aggressive debulking and platinum agents made WAI fall out of favor as a treatment of OC. Selective approaches with highly conformal radiotherapy (CRT) have been used in case of limited recurrent or unresectable disease with the potential for long-term disease control. Currently, the role of RT in OC applies for patients with recurrent oligometastatic or oligoprogressive disease and in the palliative setting for symptom control. We performed a nonsystematic review and included data from both retrospective and prospective studies focusing on the use of RT for OC and its biological rationale. Furthermore, ongoing trials on this issue are reported.

show abstract

“…Several prospective trials conducted in the 1970s showed promising results of postoperative radiation following surgery (Table 1 ) ( 25 , 29 – 35 ). Although patients with bulky disease following surgery were rarely cured, those patients with microscopic residual disease after initial cytoreductive surgery experienced disease-free survivals of 42–62% at 10 years in two randomized trials ( 29 , 30 ).…”

Section: Whole-abdomen Radiation Therapymentioning

confidence: 99%

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

et al. 2017

View full text Add to dashboard Cite

Ovarian cancer is the most lethal of the gynecologic cancers, with 5-year survival rates less than 50%. Most women present with advanced stage disease as the pattern of spread is typically with dissemination of malignancy throughout the peritoneal cavity prior to development of any symptoms. Prior to the advent of platinum-based chemotherapy, radiotherapy was used as adjuvant therapy to sterilize micrometastatic disease. The evolution of radiotherapy is detailed in this review, which establishes radiotherapy as an effective therapy for women with micrometastatic disease in the peritoneal cavity after surgery, ovarian clear cell carcinoma, focal metastatic disease, and for palliation of advanced disease. However, with older techniques, the toxicity of whole abdominal radiotherapy and the advancement of systemic therapies have limited the use of radiotherapy in this disease. With newer radiotherapy techniques, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and low-dose hyperfractionation in combination with targeted agents, radiotherapy could be reconsidered as part of the standard management for this deadly disease.

show abstract

Résultats d’un essai prospectif randomisé comparant une radiothérapie abdominopelvienne postopératoire et une chimiothérapie postopératoire dans les cancers de l’ovaire précoces

Cited by 20 publications

References 30 publications

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Radiotherapy in women with epithelial ovarian cancer: historical role, current advances, and indications

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

Contact Info

Product

Resources

About